IKZF3 and non-Hodgkin lymphoma: Notably, in an RPMI-8226 MM mouse xenograft model, CFT7455 profoundly and persistently degraded IKZF3, and its combination with Dexamethasone significantly enhanced anti-tumor efficacy.274 Similarly, in non-Hodgkin's lymphoma (NHL) models unresponsive to pomalidomide, CFT7455 demonstrated significant degradation capabilities.275 Ongoing Phase I/II trials for R/R NHL and MM have shown promising early results, with near-complete, sustained IKZF3 degradation and up to 72% reduction in serum free light chains.